Clinical features of patients with suspected thrombotic thrombocytopenic purpura following allogeneic bone marrow transplantation.*
. | Patients with Clinically Suspected TTP (n = 17) . | Patients in Whom TTP Was Not Suspected (n = 245) . | P . |
---|---|---|---|
* Adapted from reference 13. These data describe the experience with allogeneic BMT at the University of Oklahoma, 1989-1998. No patients had clinically suspected TTP following autologous stem cell transplants. Clinically suspected TTP was defined by treatment with plasma exchange. TTP is used as a comprehensive diagnostic term, including syndromes with acute renal failure that may be described as HUS. | |||
Risk factors for BMT-related complications | |||
Severe primary disease | 29% | 13% | 0.08 |
>1 transplant | 18% | % | 0.20 |
Unrelated donor | 71% | 39% | 0.02 |
HLA mismatch | 35% | 16% | 0.04 |
Occurrence of BMT-related complications | |||
Acute GVHD (grade III-IV) | 47% | 13% | <0.01 |
Bacterial sepsis | 82% | 57% | 0.04 |
Viral sepsis | 65% | 16% | <0.01 |
Fungal sepsis | 65% | 28% | <0.01 |
. | Patients with Clinically Suspected TTP (n = 17) . | Patients in Whom TTP Was Not Suspected (n = 245) . | P . |
---|---|---|---|
* Adapted from reference 13. These data describe the experience with allogeneic BMT at the University of Oklahoma, 1989-1998. No patients had clinically suspected TTP following autologous stem cell transplants. Clinically suspected TTP was defined by treatment with plasma exchange. TTP is used as a comprehensive diagnostic term, including syndromes with acute renal failure that may be described as HUS. | |||
Risk factors for BMT-related complications | |||
Severe primary disease | 29% | 13% | 0.08 |
>1 transplant | 18% | % | 0.20 |
Unrelated donor | 71% | 39% | 0.02 |
HLA mismatch | 35% | 16% | 0.04 |
Occurrence of BMT-related complications | |||
Acute GVHD (grade III-IV) | 47% | 13% | <0.01 |
Bacterial sepsis | 82% | 57% | 0.04 |
Viral sepsis | 65% | 16% | <0.01 |
Fungal sepsis | 65% | 28% | <0.01 |